Thambi Dorai

Title: Thambi Dorai: Innovator in Cancer Therapeutics

Introduction

Thambi Dorai is a notable inventor based in Nanuet, NY (US). He has made significant contributions to the field of cancer research, particularly through his innovative patent related to the EGFR pathway and its implications in tumorigenic functions.

Latest Patents

Thambi Dorai holds a patent for his invention titled "MN/CA IX and EGFR pathway inhibition." This invention is based on the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. The patent reveals that EGFR-phosphorylated CA IX interacts with the p85 subunit of PI3K to activate Akt, which is associated with anti-apoptotic functions and increased cell survival. This finding indicates a positive feedback loop for CA IX expression mediated by the PI3K pathway in preneoplastic and neoplastic diseases. The patent also discloses novel therapeutic methods for treating these diseases associated with abnormal MN/CA IX expression, utilizing EGFR pathway inhibitors, preferably tyrosine kinase inhibitors or EGFR-specific antibodies. Furthermore, methods for patient therapy selection based on the detection of abnormal MN/CA IX gene expression in preneoplastic and neoplastic tissues are also included.

Career Highlights

Thambi Dorai is affiliated with the Institute of Virology of the Slovak Academy of Sciences, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential to improve treatment options for patients suffering from various forms of cancer.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Thambi Dorai's innovative work in understanding the EGFR pathway and its role in cancer progression highlights the importance of targeted therapies in modern medicine. His contributions pave the way for new treatment strategies that could significantly impact patient outcomes.